The DOI matches its Crossref record; 102 of the 104 references it cites were found in a registry or an index.
Memantine: a review of studies into its safety and efficacy in treating Alzheimer’s disease and other dementias
Open accessAbstract
Memantine: a review of studies into its safety and efficacy in treating Alzheimer’s disease and other dementias Stuart J Thomas, George T GrossbergDepartment of Neurology and Psychiatry, Saint Louis University School of Medicine, St. Louis, MO, USAAbstract: Memantine is an uncompetitive N-methyl-D-aspartate receptor antagonist with moderate affinity. Its mechanism of action is neuroprotective and potentially therapeutic in several neuropsychiatric diseases. It has been approved by the FDA for the treatment of moderate to severe Alzheimer’s disease (AD) either as a monotherapy or in combination with cholinesterase inhibitors. This review covers key studies of memantine’s safety and efficacy in treating moderate to severe AD. It also covers current research into other dementias including but not exclusively mild AD and vascular dementia. Other studies on the efficacy of memantine for other neuropsychiatric diseases are discussed. Memantine is a safe and effective drug that merits further research on several topics. Clinicians should be aware of new studies and potential uses of memantine because of its safety and efficacy.Keywords: memantine, Alzheimer’s disease, dementia
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Patients taking memantine experience adverse effects like fatigue, pain, confusion, urinary incontinence, urinary tract infection, peripheral edema, etc. [35].”
From Indian Medicinal Herbs and Formulations for Alzheimer’s Disease, from Traditional Knowledge to Scientific Assessment (2020) · cites this paper as [35]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Memantine in Moderate-to-Severe Alzheimer's Disease
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043
Bonfoco, E., Krainc, D., Ankarcrona, M., Nicotera, P., & Lipton, S. A. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.16.7162 · Cited by 1,958
Tariot, P. N., Farlow, M. R., Grossberg, G. T., Graham, S. M., McDonald, S., Gergel, I., & for the Memantine Study Group (2004) · JAMA · doi:10.1001/jama.291.3.317 · Cited by 1,403
Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond
Lipton, S. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1958 · Cited by 909
Chen, H., Pellegrini, J. W., Aggarwal, S., Lei, S., Warach, S. J., Jensen, F., & Lipton, S. A. (1992) · Journal of Neuroscience · doi:10.1523/jneurosci.12-11-04427.1992 · Cited by 628
β-Amyloid protein increases the vulnerability of cultured cortical neurons to excitotoxic damage
Koh, J., Yang, L. L., & Cotman, C. W. (1990) · Brain Research · doi:10.1016/0006-8993(90)91355-k · Cited by 617
Orgogozo, J.-M., Rigaud, A.-S., Stöffler, A., Möbius, H.-J., & Forette, F. (2002) · Stroke · doi:10.1161/01.str.0000020094.08790.49 · Cited by 539
Kavirajan, H., & Schneider, L. S. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70195-3 · Cited by 497
Post Stroke Pain: Identification, Assessment, and Therapy
Harrison, R. A., & Field, T. S. (2015) · Cerebrovascular Diseases · doi:10.1159/000375397 · Cited by 434
A Double-Blind, Placebo-Controlled Study of Memantine in the Treatment of Major Depression
Zarate, C. A., Singh, J. B., Quiroz, J. A., De Jesus, G., Denicoff, K. K., Luckenbaugh, D. A., Manji, H. K., & Charney, D. S. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.153 · Cited by 387
Research works printed but not linked: 1
- [97]Grossberg GT Manes F Allegri R A multinational, randomized, double-blind, placebo-controlled, parallel-group trial of memantine extended-release capsule (28 mg, once daily) in patients with moderate to severe Alzheimer’s disease. [poster] 133rd Annual Meeting of the American Neurological Association September 21–24, 2008 Salt Lake City, UT, USA Clinical Interventions in Aging is an international, peer-reviewed journal focusing on evidence-based reports on the value or lack thereof of treatments intended to prevent or delay the onset of maladaptive correlates of aging in human beings This journal is indexed on PubMed Central, MedLine, the American Chemical Society’s ‘Chemical Abstracts Service’ (CAS), Scopus and the Elsevier Bibliographic databases. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.
Cited by
Sorted by citations
Drug candidates in clinical trials for Alzheimer’s disease
Hung, S.-Y., & Fu, W.-M. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0355-7 · Cited by 420
O'Brien, J. T., Holmes, C., Jones, M. S., Jones, R. W., Livingston, G., McKeith, I. G., Mittler, P. J., Passmore, P., Ritchie, C. W., Robinson, L. A., et al. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881116680924 · Cited by 361
Neurotherapeutic applications of nanoparticles in Alzheimer’s disease
Sahni, J. K., Doggui, S., Ali, J., Baboota, S., Dao, L., & Ramassamy, C. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.11.033 · Cited by 219
Combination Drug Therapy for the Management of Alzheimer’s Disease
Kabir, M. T., Uddin, M. S., Mamun, A. A., Jeandet, P., Aleya, L., Mansouri, R. A., Ashraf, G. M., Mathew, B., Bin-Jumah, M. N., & Abdel-Daim, M. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093272 · Cited by 217
Neuroprotective effects of theanine and its preventive effects on cognitive dysfunction
Kakuda, T. (2011) · Pharmacological Research · doi:10.1016/j.phrs.2011.03.010 · Cited by 124
Metadata
- Authors
- Grossberg, G., & Thomas, S.
- Affiliations
- Saint Louis University (US)
- Corresponding author
- Grossberg, George
- ORCID
- Grossberg, George
- Venue
- Clinical Interventions in Aging
- Publisher
- Informa UK Limited
- Published
- 2009-09
- Volume
- 4
- Pages
- 367
- ISSN
- 1176-9092 (ISSN-L)
- 1178-1998
- PMC
- PMC2762361
- OpenAlex
- W2008348302
- Cited by
- 151
- References
- 104
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 4 · 2023: 8 · 2022: 7 · 2021: 11 · 2020: 10 · 2019: 12 · 2018: 3 · 2017: 17 · 2016: 6 · 2015: 8 · 2014: 10 · 2013: 10 · 2012: 7
- FWCI
- 1.42
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Clinical Interventions in Aging (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- memantine, Alzheimer's disease, dementia, NMDA receptor antagonists, drug safety, drug efficacy, cholinesterase inhibitors, vascular dementia, mild Alzheimer's disease, neuroprotection, neuropsychiatric disorders
- MeSH terms
- Alzheimer Disease, Dementia, Humans, Memantine, Severity of Illness Index, Dopamine Agents, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
